Compare JUBILANT LIFE SCIENCES with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs SANOFI INDIA - Comparison Results

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES SANOFI INDIA JUBILANT LIFE SCIENCES/
SANOFI INDIA
 
P/E (TTM) x 15.2 34.8 43.8% View Chart
P/BV x 1.8 6.1 29.2% View Chart
Dividend Yield % 0.8 1.4 58.6%  

Financials

 JUBILANT LIFE SCIENCES   SANOFI INDIA
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-19
SANOFI INDIA
Dec-18
JUBILANT LIFE SCIENCES/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs8986,840 13.1%   
Low Rs6184,630 13.3%   
Sales per share (Unadj.) Rs572.01,203.1 47.5%  
Earnings per share (Unadj.) Rs36.2165.3 21.9%  
Cash flow per share (Unadj.) Rs59.5209.9 28.4%  
Dividends per share (Unadj.) Rs4.5084.00 5.4%  
Dividend yield (eoy) %0.61.5 40.5%  
Book value per share (Unadj.) Rs301.9963.6 31.3%  
Shares outstanding (eoy) m159.2823.03 691.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.34.8 27.8%   
Avg P/E ratio x20.934.7 60.3%  
P/CF ratio (eoy) x12.727.3 46.6%  
Price / Book Value ratio x2.56.0 42.2%  
Dividend payout %12.450.8 24.4%   
Avg Mkt Cap Rs m120,694132,078 91.4%   
No. of employees `0002.43.3 72.4%   
Total wages/salary Rs m19,2604,068 473.4%   
Avg. sales/employee Rs Th38,120.68,393.8 454.2%   
Avg. wages/employee Rs Th8,058.41,232.4 653.9%   
Avg. net profit/employee Rs Th2,414.31,153.0 209.4%   
INCOME DATA
Net Sales Rs m91,10827,708 328.8%  
Other income Rs m357897 39.8%   
Total revenues Rs m91,46628,605 319.8%   
Gross profit Rs m17,3906,235 278.9%  
Depreciation Rs m3,7091,027 361.1%   
Interest Rs m2,1987 31,401.4%   
Profit before tax Rs m11,8406,098 194.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-2,8020-   
Tax Rs m3,2682,292 142.6%   
Profit after tax Rs m5,7703,806 151.6%  
Gross profit margin %19.122.5 84.8%  
Effective tax rate %27.637.6 73.4%   
Net profit margin %6.313.7 46.1%  
BALANCE SHEET DATA
Current assets Rs m45,84815,922 288.0%   
Current liabilities Rs m20,8976,235 335.2%   
Net working cap to sales %27.435.0 78.3%  
Current ratio x2.22.6 85.9%  
Inventory Days Days5764 89.2%  
Debtors Days Days5121 244.1%  
Net fixed assets Rs m65,4987,539 868.8%   
Share capital Rs m159230 69.3%   
"Free" reserves Rs m47,93021,962 218.2%   
Net worth Rs m48,08922,192 216.7%   
Long term debt Rs m42,4290-   
Total assets Rs m114,68529,839 384.3%  
Interest coverage x6.4872.1 0.7%   
Debt to equity ratio x0.90-  
Sales to assets ratio x0.80.9 85.6%   
Return on assets %6.912.8 54.4%  
Return on equity %12.017.2 70.0%  
Return on capital %12.427.5 45.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,4227,587 163.7%   
Fx outflow Rs m17,2277,145 241.1%   
Net fx Rs m-4,805442 -1,087.1%   
CASH FLOW
From Operations Rs m11,2153,739 299.9%  
From Investments Rs m-10,118-731 1,384.2%  
From Financial Activity Rs m6,574-1,972 -333.4%  
Net Cashflow Rs m7,6121,036 734.8%  

Share Holding

Indian Promoters % 45.6 0.0 -  
Foreign collaborators % 3.5 60.4 5.8%  
Indian inst/Mut Fund % 8.7 14.4 60.4%  
FIIs % 21.2 14.6 145.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.1 10.5 201.0%  
Shareholders   23,815 15,184 156.8%  
Pledged promoter(s) holding % 15.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   ORCHID PHARMA LTD  CIPLA  ASTRAZENECA PHARMA  VENUS REMEDIES  STERLING BIOTECH  

Compare JUBILANT LIFE SCIENCES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Lower; Oil & Gas and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended lower. At the closing bell, the BSE Sensex stood lower by 262 points (down 0.7%).

Related Views on News

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY20); Net Profit Down 7.7% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 7.7% YoY). Sales on the other hand came in at Rs 22 bn (up 5.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY19); Net Profit Down 166.0% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 1 bn (down 166.0% YoY). Sales on the other hand came in at Rs 24 bn (up 5.9% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY19); Net Profit Up 12.6% (Quarterly Result Update)

May 8, 2019 | Updated on May 8, 2019

For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Sep 16, 2019 (Close)

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES - FULFORD INDIA COMPARISON

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS